GlassScriptPhysician profile
Amarendar Kasarla
NPI 1104813260
$2,279.13
in general payments reported to CMS, 2019-2025
14 companies · $249 in 2025
The $249 reported for 2025 was more than what 84% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $302 · 2021: $553 · 2022: $52.43 · 2023: $199 · 2024: $420 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $835.66 | 2019-2025 | Eterna, Octrode, Proclaim |
| Medtronic, INC. | $268.55 | 2021-2025 | Abre, Intellis Adaptivestim, Synchromedii |
| Medtronic USA, INC. | $247.73 | 2019-2020 | |
| Nevro Corp. | $215.38 | 2019-2024 | Senza |
| Boston Scientific Corporation | $207.98 | 2019-2025 | Intracept |
| Saluda Medical Americas, INC. | $127.96 | 2024-2025 | Evoke |
| Acacia Pharma INC | $104.68 | 2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $71.30 | 2019 | |
| Globus Medical, INC. | $29.56 | 2025 | Vyrsa V1 |
| Arbor Pharmaceuticals, INC. | $24.71 | 2021-2022 | |
| Spinal Simplicity, LLC | $18.01 | 2024 | Ha Minuteman G3-R |
| Stryker Corporation | $16.68 | 2020 | |
| Stimwave Technologies Incorporated | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarendar Kasarla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.